Osteoclast-like giant cell-rich variant of anaplastic thyroid carcinoma is extremely uncommon. In this paper we describe one such case in a 50 year-old male. The patient presented with enlarged cervical lymph node after initial total thyroidectomy. The fine needle aspiration cytology (FNAC) smear showed abundant multinucleated osteoclastic-like giant cells and scattered large bizarre tumour cells. FNAC of such cases may often be mistaken as osteoclast-like giant cell-rich lesions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cyt.13104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Keratin Positive Giant Cell Rich Tumor of the Pelvic Bone with a Fusion: A Case Report.
Int J Surg Pathol
January 2025
Department of orthopedic oncology, UZ Leuven, Leuven, Belgium.
Keratin positive giant cell rich tumor is a rare mesenchymal tumor first described in 2025. It can occur in both soft tissue and bone and predominantly affects young women. The tumor's biological behavior remains uncertain despite its low-grade classification.
View Article and Find Full Text PDFIntraarticular Nodular Fasciitis of the Elbow Confirmed by Gene Fusion.
Int J Surg Pathol
December 2024
Department of Orthopedics, Osaka General Medical Center, Osaka, Japan.
Nodular fasciitis is a benign, usually self-limiting myofibroblastic proliferation with a predilection for the upper extremities, trunk, and head and neck, and almost all of which harbor the fusion. Since nodular fasciitis is not widely recognized to arise within the joints, it may therefore cause diagnostic confusion in this uncommon setting. We report an unusual tumor of an 11-year-old patient who presented with a 6-month history of right elbow swelling and pain.
View Article and Find Full Text PDFEstablishment and characterization of NCC-GCTB10-C1: a novel cell line derived from a patient with recurrent giant cell tumor of bone.
Hum Cell
December 2024
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Giant cell tumor of bone (GCTB) is a rare osteolytic tumor composed of mononuclear stromal cells, macrophages, and osteoclast-like giant cells. While generally benign, GCTB has a high risk of local recurrence and can occasionally undergo malignant transformation or metastasis, posing significant clinical challenges. The primary treatment is complete surgical resection; however, effective management strategies for recurrent or advanced GCTB remain elusive, underscoring the need for further preclinical research.
View Article and Find Full Text PDFIntroduction: Brown tumors are benign lesions caused by hyperparathyroidism and characterized by increased osteoclast activity and mass effect, which can lead to paraplegia when the spine is involved. Secondary hyperparathyroidism is common in patients on long-term hemodialysis therapy.
Case Report: We report the case of a 48-year-old man on regular dialysis who presented with leg weakness as well as back pain and was diagnosed with secondary hyperparathyroidism and thoracic spine tumor.
PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE.
J Ayub Med Coll Abbottabad
December 2024
Combined Military Hospital, Rawalpindi-Pakistan.
Article Synopsis
- Giant cell tumour of bone (GCTB) is a rare benign tumor that mainly affects young adults (ages 20-40) and is classified as an intermediate malignant tumor by the WHO, with its pathology linked to the expression of RANKL.
- A study conducted over 36 months at a military hospital investigated the effects of preoperative denosumab therapy on GCTB patients, measuring pain and functional status before and after treatment.
- Results showed significant improvement in pain and function, shifting the intended surgical approach from more invasive procedures like joint resection to less aggressive options such as intralesional curettage post-denosumab therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!